Literature DB >> 21468597

TP53 codon 72 polymorphism is associated with pancreatic cancer risk in males, smokers and drinkers.

Takayuki Sonoyama1, Akiko Sakai, Yuichiro Mita, Yukiko Yasuda, Hirofumi Kawamoto, Takahito Yagi, Masao Yoshioka, Tetsushige Mimura, Kei Nakachi, Mamoru Ouchida, Kazuhide Yamamoto, Kenji Shimizu.   

Abstract

Tumor protein p53 (TP53) is the best-known tumor suppressor gene and plays a crucial role in carcinogenesis. The TP53 Arg 72 Pro polymorphism has been reported to be a risk factor for several types of cancer, but its association with pancreatic cancer has not been fully evaluated. Therefore, we investigated the effects of this polymorphism on pancreatic cancer in relation to smoking and drinking habits by examining the distribution of the SNP genotypes in 226 pancreatic cancer patients and 448 healthy controls. The frequencies of Arg/Arg, Arg/Pro and Pro/Pro were found to be 37, 49 and 15% in the pancreatic cancer cases and 44, 46 and 10% in the controls, respectively. Compared to the controls with the Arg/Arg genotype, cases with Pro/Pro homozygosity exhibited a significantly increased risk [adjusted odds ratio (OR)=1.70; 95% confidence interval (CI) 1.01-2.88]. In stratified studies, the association was particularly strong in males (OR=2.62; 95% CI 1.32-5.23), particularly in those smoking in excess of 20 pack-years and drinking in excess of 23 g ethanol/day (OR=5.02; 95% CI 1.12-22.51). We found that the TP53 Pro/Pro genotype compared to the Arg/Arg genotype had a profound effect on pancreatic cancer risk among males, particularly among heavy smokers and excessive alcohol drinkers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468597     DOI: 10.3892/mmr.2011.449

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  11 in total

1.  Potential functional variants in SMC2 and TP53 in the AURORA pathway genes and risk of pancreatic cancer.

Authors:  Yun Feng; Hongliang Liu; Bensong Duan; Zhensheng Liu; James Abbruzzese; Kyle M Walsh; Xuefeng Zhang; Qingyi Wei
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

Review 2.  Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis.

Authors:  Navneet Momi; Sukhwinder Kaur; Moorthy P Ponnusamy; Sushil Kumar; Uwe A Wittel; Surinder K Batra
Journal:  Carcinogenesis       Date:  2012-05-23       Impact factor: 4.944

Review 3.  Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.

Authors:  Mohammad Haroon Khan; Aftab Khalil; Hamid Rashid
Journal:  Genet Res (Camb)       Date:  2015-04-17       Impact factor: 1.588

4.  Associations of GSTM1 and GSTT1 polymorphisms with pancreatic cancer risk: evidence from a meta-analysis.

Authors:  Yue Fan; Wen Zhang; Chen-Ye Shi; Ding-Fang Cai
Journal:  Tumour Biol       Date:  2012-11-27

5.  Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.

Authors:  Yasuki Hori; Katsuyuki Miyabe; Michihiro Yoshida; Takahiro Nakazawa; Kazuki Hayashi; Itaru Naitoh; Shuya Shimizu; Hiromu Kondo; Yuji Nishi; Shuichiro Umemura; Akihisa Kato; Hirotaka Ohara; Hiroshi Inagaki; Takashi Joh
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

6.  Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials.

Authors:  Ishwaria M Subbiah; Gerald S Falchook; Ahmed O Kaseb; Kenneth R Hess; Apostolia M Tsimberidou; Siqing Fu; Vivek Subbiah; David S Hong; Aung Naing; Sarina A Piha-Paul; Owais Akmal; Filip Janku; Razelle Kurzrock
Journal:  Oncotarget       Date:  2015-09-29

Review 7.  An Overview of Genetic Changes and Risk of Pancreatic Ductal Adenocarcinoma.

Authors:  Agnieszka K Sarnecka; Malgorzata Zagozda; Marek Durlik
Journal:  J Cancer       Date:  2016-10-22       Impact factor: 4.207

8.  Detection of human papillomavirus (HPV) DNA prevalence and p53 codon 72 (Arg72Pro) polymorphism in prostate cancer in a Greek group of patients.

Authors:  Vasiliki Michopoulou; Stavros P Derdas; Emmanouil Symvoulakis; Nikolaos Mourmouras; Alexandros Nomikos; Dimitris Delakas; George Sourvinos; Demetrios A Spandidos
Journal:  Tumour Biol       Date:  2014-09-12

Review 9.  CHIP: A new modulator of human malignant disorders.

Authors:  Zhe Cao; Guanqiao Li; Qianqian Shao; Gang Yang; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  Oncotarget       Date:  2016-05-17

10.  Pathogenic Mutations in Cancer-Predisposing Genes: A Survey of 300 Patients with Whole-Genome Sequencing and Lifetime Electronic Health Records.

Authors:  Karen Y He; Yiqing Zhao; Elizabeth W McPherson; Quan Li; Fan Xia; Chunhua Weng; Kai Wang; Max M He
Journal:  PLoS One       Date:  2016-12-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.